Download MendeleyDiscovery and Optimization of Selective Inhibitors of Large Tumor Suppressor Kinases LATS1 and 2 for In Vivo Investigation of the Hippo-YAP Pathway in Tissue Regeneration.
Namoto, K., Vangrevelinghe, E., Machauer, R., Behnke, D., Buschmann, N., Lachal, J., Schipp, K., Sorge, M., Barker, K., Fabbiani, F., Piechon, P., Connor, L.E., Laurent, S., Lohmann, F., Unterreiner, V., George, E.L., Redmond, E., Wang, L., Scheufler, C., Sohal, B., Sailer, A.W., Glatthar, R., Tchorz, J.S., Maibaum, J.(2025) J Med Chem 68: 13591-13608
- PubMed: 40574495
- DOI: https://doi.org/10.1021/acs.jmedchem.5c00350
- Primary Citation of Related Structures:
9HFP - PubMed Abstract:
Large Tumor Suppressor kinases LATS1 and 2 (LATS1/2) are serine/threonine kinases and core regulators of the Hippo-YAP pathway. Inhibition of LATS1/2 promotes nuclear translocation of nonphosphorylated YAP, thereby initiating a downstream cascade promoting cell proliferation. We set out to investigate the potential of LATS inhibition as a therapeutic approach to enhance tissue regeneration and hereby report a structure-guided optimization of screening hit 1 for potency, binding efficiency, and physicochemical properties, leading to a highly selective, cellularly active, and orally available tool compound 7 (NIBR-LTSi) that demonstrated ex vivo target engagement and in vivo YAP target gene activation in rodents.
- Novartis Biomedical Research, CH-4002 Basel, Switzerland.
Organizational Affiliation:
